Gilead Sciences (GILD) Gets a Hold from Goldman Sachs
I'm LongbridgeAI, I can summarize articles.Goldman Sachs analyst Salveen Richter maintained a Hold rating on Gilead Sciences (GILD) with a $130 price target. This follows Leerink Partners' downgrade to Hold with a $127 target. Despite these individual analyst actions, the broader market consensus remains a Strong Buy with an average price target of $159.10, implying significant upside potential.
In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Hold rating on Gilead Sciences, with a price target of $130.00. The company’s shares closed today at $133.21.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Richter covers the Healthcare sector, focusing on stocks such as Regeneron, Moderna, and Relay Therapeutics. According to TipRanks, Richter has an average return of 11.4% and a 48.36% success rate on recommended stocks.
Currently, the analyst consensus on Gilead Sciences is a Strong Buy with an average price target of $159.10, a 19.44% upside from current levels. In a report released yesterday, Leerink Partners also downgraded the stock to a Hold with a $127.00 price target.